Browsing tag:

chronic heart failure


Entresto, the novel combination therapy which combines Sacubitril and Valsartan, was FDA approved on July 7, 2015. Previously known as the investigational compound LCZ696, Entresto received an FDA nod to reduce the risk of both hospitalization and cardiovascular mortality in patients with chronic heart failure, especially those with a reduced ejection fraction and an NYHA[…]

Read More

Ivabradine, also known as the brand name drug Procorlan which is marketed by Servier, recently received a fast track from the FDA for the treatment of chronic heart failure. As an efficacious drug which inhibits the IF current in the sinoatrial node, Ivabradine has proven to be a virtuous symptomatic treatment for chronic stable angina[…]

Read More

Carvedilol Phosphate, CAS number 72956-09-3, is known as the blockbuster medication Coreg CR. GlaxoSmithKline holds the patent for Coreg CR until February 7, 2016. Useful for treating patients with hypertension and mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, carvedilol phosphate is available for research and development from LGM Pharma. In the group of[…]

Read More

A study presented at the European Society of Cardiology (ESC) Congress 2010 gives promising results to patients suffering from heart failure with tachycardia (increased heart rate). The study, called Systolic Heart Failure Treatment with If Inhibitor Ivabradine Trial (SHIFT), provided scientists with a strong case for ivabradine’s usefulness as an adjunct agent in the treatment[…]

Read More